(Q45143154)

English

Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC).

scientific article published in January 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15531895%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC) (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15531895%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

0 references

Ibrahim Yakoub-Agha

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15531895%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

author name string

Mohty M

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15531895%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Attal M

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15531895%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Marit G

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15531895%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Bulabois CE

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15531895%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Garban F

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15531895%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Gratecos N

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15531895%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Rio B

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15531895%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Vernant JP

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15531895%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Sotto JJ

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15531895%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Cahn JY

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15531895%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Blaise D

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15531895%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Jouet JP

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15531895%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Facon T

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15531895%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

language of work or name

0 references

publication date

1 January 2005

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15531895%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Bone Marrow Transplantation

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15531895%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

35

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15531895%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15531895%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

165-169

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15531895%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704756

0 references

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704756

21 January 2018

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704756

21 January 2018

Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704756

21 January 2018

Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704756

21 January 2018

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704756

21 January 2018

Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704756

21 January 2018

Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704756

21 January 2018

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704756

21 January 2018

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704756

21 January 2018

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704756

21 January 2018

Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704756

21 January 2018

Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704756

7 January 2021

based on heuristic

inferred from DOI database lookup

Graft-versus-myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704756

7 January 2021

based on heuristic

inferred from DOI database lookup

Donor leukocyte infusions for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704756

7 January 2021

based on heuristic

inferred from DOI database lookup

High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704756

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704756

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704756

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide for the treatment of chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704756

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704756

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1704756

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15531895%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15531895%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45143154&oldid=1465421572"